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Nonmyeloablative (NMA) regimens allow the use of allogeneic hematopoietic stem cell transplantation (allo-
HSCT) in patients considered unﬁt for standard myeloablative conditioning (MAC) regimens using high-dose
alkylating agents with or without total body irradiation (TBI). Reduced-intensity conditioning (RIC) regimens,
based on ﬂudarabine (Flu), busulfan (Bu), and rabbit antithymocyte globulin (r-ATG), represent an interme-
diate alternative between NMA and MAC regimens. This platform was subsequently optimized by the
introduction of i.v. Bu and the use of 5 mg/kg r-ATG, based on the hypothesis that these modiﬁcations would
improve the safety of RIC allo-HSCT. Here we report a study conducted at our institution on 206 patients,
median age 59 years, who underwent allo-HSCT after conditioning with Flu, 2 days of i.v. Bu, and 5 mg/kg
r-ATG (FBx-ATG) between 2005 and 2012. The prevalence of grade III-IV acute graft-versus-host disease
(GVHD) was 9%, and that of extensive chronic GVHD was 22%. Four-year nonrelapse mortality (NRM), relapse,
and overall survival (OS) rates were 22%, 36%, and 54%, respectively. NRM tended to be inﬂuenced by
comorbidities (hematopoietic cell transplantationespeciﬁc comorbidity index [HCT-CI] <3 versus HCT-CI 3:
18% versus 27%; P ¼ .075), but not by age (<60 years, 20% versus 60 years, 25%; P ¼ .142). Disease risk
signiﬁcantly inﬂuenced relapse (2 years: low, 8%, intermediate, 28%, high, 34%; very high, 63%; P ¼ .017). Both
disease risk (hazard ratio [95% conﬁdence interval]: intermediate, 2.1 [0.8 to 5.2], P ¼ .127; high, 3.4 [1.3 to
9.1], P ¼ .013; very high, 4.0 [1.1 to 14], P ¼ .029) and HCT-CI (hazard ratio [95% conﬁdence interval]: HCT-CI
3, 1.7 (1.1 to 2.8), P ¼ .018) inﬂuenced OS, but age and donor type did not. The FBx-ATG RIC regimen reported
here is associated with low mortality and high long-term disease-free survival without persistent GVHD in
both young and old patients. It represents a valuable platform for developing further post-transplantation
strategies aimed at reducing the incidence of relapse, particularly in the setting of high-risk disease.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION in higher disease control, but also in higher NRM compared
Nonmyeloablative (NMA) regimens allow the use of allo-
geneic hematopoietic stemcell transplantation (allo-HSCT) in
patients unﬁt for standardmyeloablative conditioning (MAC)
regimens, such as cyclophosphamide (Cy) and full-dose total
body irradiation (TBI; 12 Gy) or Cy and busulfan (Bu). NMA
regimens are associated with reduced nonrelapse mortality
(NRM) and exert disease control relying solely on the allo-
geneic graft-versus-tumor immune reaction [1,2].
Reduced-intensity conditioning (RIC) regimens deliver a
higher degree of myeloablation than NMA regimens but a
lower level thanMAC regimens. RIC regimens usually include
an intermediate dose of alkylating agents, and thus retain a
direct antitumor effect, with the risk of higher NRM [3,4]. We
previously reported that an RIC regimen composed of an
intermediate dose of oral Bu and a low dose of r-ATG resultededgments on page 373.
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13.11.030with a 2-Gy TBI NMA conditioning regimen, with similar
overall outcomes [5,6]. We found that with such a condi-
tioning regimen, both graft-versus-host disease (GVHD) and
NRM could be satisfactorily controlled without loss of dis-
ease control by only a marginal increase in r-ATG dose and a
switch from oral to i.v. Bu [7,8].
Here we report the outcome of the ﬁrst 206 consecutive
patients who were treated with this protocol before under-
going allo-HSCT from an HLA-identical related donor or an
unrelated donor. With a minimal follow-up of 7 months and
a median follow-up of 28 months, our results strongly sug-
gest that although the population is characterized by high-
risk features, this protocol allows for an encouragingly high
survival rate without disease recurrence or persistent
debilitating chronic GVHD.
PATIENTS AND METHODS
Selection Criteria
Patients with the following criteria were included in our analyses: (1)
allo-HSCT performed between 2005 and 2012; (2) RIC based on Flu, i.v. BuTransplantation.
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(MRD) or 10/10 HLA-matched unrelated donor (MUD); and (4) peripheral
blood stem cells (PBSCs) as the graft source. Our Institutional Review Board
approved this study, and all patients provided informed consent in accor-
dance with the Declaration of Helsinki.
Conditioning Regimen and GVHD Prophylaxis
The FBx-ATG conditioning regimen was started on day -6 and included
Flu (Fludara; Bayer, Puteaux, France) 30 mg/m2 daily from day -5 to day -1,
Bx (Busilvex, Pierre Fabre, Boulogne-Billancourt, France) 130 mg/m2 once
daily on days -4 and -3, and r-ATG (Thymoglobuline, Genzyme, St. Germain-
en-Lay, France) 2.5 mg/kg once daily on days 2 and 1 or on days 3
and 2, as reported previously [9]. Cyclosporine A (Sandimmun; Novartis,
Bâle, Switzerland), started on day 1, was used for postgraft immunosup-
pression. Stem cell harvesting and supportive care were performed as
described previously [5].
Stratiﬁcation of Risk of Relapse and NRM
The risk of relapse in our cohort of patients with different hematologic
diseases was characterized using the disease risk index (DRI) as described by
Armand et al. [10]. Comorbidities were assessed using the hematopoietic
cell transplantationespeciﬁc comorbidity index (HCT-CI) [11].
Study Endpoints and Statistical Analysis
The cumulative incidence of GVHD was calculated as described previ-
ously [12,13]. NRM and relapse were determined using the Prentice esti-
mation and the Gray test, which allow consideration of competing events
[14,15]. Progression-free survival (PFS) and OS were calculated with the
Kaplan-Meier method and the log-rank test [16]. In patients who survived
without disease recurrence, the prevalence of immunosuppressive treat-
ments served as a surrogate marker of quality of life. Time to events was
calculated from the date of allo-SCT. Cox regression was used to analyze the
impact of pretransplantation covariates in multivariate analyses of PFS and
OS [17]. All survival analyses were performed using R version 2.13.1 (http://
www.R-project.org).
RESULTS
Patient and Transplantation Characteristics
A total of 206 consecutive patients were included in our
analyses. Baseline patient and transplantation characteristics
are described in Table 1. The median patient agewas 59 years
(range, 19 to 71 years), and 32 patients were age 65 years.
One hundred and twenty-four patients (60%) underwent
transplantation from an MRD. Only 25 patients (12%) pre-
sented with a low disease risk index, and 90 patients (46%)
had an HCT-CI 3. Seventy-six patients (37%) were not inTable 1
Patient, Disease, and Transplantation Characteristics (n ¼ 206)
Characteristic Value
Age, yr, median (range) 59 (19-71)
Donor, n (%)
MRD 123 (60)
MUD 83 (40)
Diagnosis, n (%)
Acute myelogenous leukemia 70 (34)
Myelodysplastic syndrome 19 (9)
Acute lymphoblastic leukemia 9 (4)
Non-Hodgkin lymphoma 41 (20)
Hodgkin lymphoma 14 (7)
Chronic lymphoblastic leukemia 14 (7)
Multiple myeloma 31 (15)
Myeloproliferative neoplasm 6 (3)
Chronic myelogenous leukemia 2 (1)
Disease risk index, n (%)
Low 25 (12)
Intermediate 125 (61)
High 48 (23)
Very high 8 (4)
HCT-CI, n (%)
0-2 107 (54)
3 90 (46)
Unknown 9complete remission at the time of transplantation. The me-
dian duration of post-transplantation follow-up was
28 months (range, 7 to 76 months).
GVHD, NRM, and Relapse
Post-transplantation events and outcomes of the 206
patients are presented in Table 2. All but 1 patient engrafted.
The cumulative incidence of grade III-IV acute GVHD was 9%,
and that of extensive chronic GVHD was 22%. The incidence
of grade III-IV acute GVHD was higher in patients age
60 years (14% versus 5% in those age <60 years; P ¼ .021),
that of extensive chronic GVHD was similar in the 2 age
groups (25% in those age <60 years versus 19% in those aged
60 years; P¼ .367). Forty-three patients died of nonrelapse-
related causes at a median of 6 months (range, 0.4 to
30 months) after allo-HSCT. NRM was estimated at 5% (95%
conﬁdence interval [CI], 2% to 8%) at day þ100, 16% (95% CI,
12% to 22%) at 1 year, and 22% (95% CI, 16% to 29%) at 4 years
(Figure 1A). NRM was only marginally inﬂuenced by
comorbidities (18% in patients with HCT-CI <3 versus 27% in
those with HCT-CI 3; P ¼ .075), and was not inﬂuenced by
age (20% in patients age <60 years versus 25% in those age
60 years; P ¼ .142). Sixty-three patients experienced dis-
ease recurrence, at a median time of 7 months (range, 0.3 to
68 months) after allo-HSCT, for a 2-year cumulative inci-
dence of relapse of 28% (95% CI, 22% to 34%) (Figure 1A). DRI
had a signiﬁcant correlation with the incidence of relapse at
2 years (low, 8%; intermediate, 28%; high, 34%; very high,
63%; P ¼ .017).
PFS and OS
One-year PFS was 63% (95% CI, 56% to 70%), and 1-year OS
was 73% (95% CI, 67% to 79%) (Figure 1B). The causes of death
are listed in Table 3. Multivariate analyses showed that age
(<60 versus60 years) or the donor type (MRD versus MUD)
did not inﬂuence PFS and OS (Table 4). For PFS, DRI was the
most signiﬁcant predictive factor, and the predictive value of
HCT-CI was close to signiﬁcance (Table 4). HCT-CI (2-year OS,
73% for <3 versus 54% for 3; P ¼ .020; Figure 2A) and DRI
(2-year OS, 84% for low versus 68% for intermediate versus
47% for high versus 25% for very high; P ¼ .008; Figure 2B)
had a signiﬁcant inﬂuence on OS (Table 4).
Immunosuppressive Treatment and GVHD in 1-Year
Progression-Free Survivors
At 1 year after allo-HSCT, 122 patients were alive and
progression-free. Among these survivors, 96 (79%) were
surviving without GVHD without immunosuppressive
treatment (IST) (n¼ 89; 73%) or with tapering IST (n¼ 7; 6%).
Seven patients (6%) were surviving with IST for persistent
extensive chronic GVHD.Table 2
Outcomes after Allo-SCT (n ¼ 206)
Outcome Value
Acute GVHD, n (%)
Grade II-IV 23 (17-29)
Grade III-IV 9 (5-13)
Chronic GVHD, n (%)
Overall 37 (30-44)
Extensive 22 (17-28)
NRM at 4 yr, n (%) 22 (16-29)
Relapse at 4 yr, n (%) 36 (28-44)
PFS at 4 yr, n (%) 41 (34-50)
OS at 4 yr, n (%) 54 (46-64)
Follow-up, mo, median (range) 28 (7-76)
Figure 1. Outcomes after allo-HSCT. Cumulative incidence of NRM and
Relapse (A). Kaplan Meier estimation of OS and PFS (B).
Table 4
Multivariate Analyses of PFS and OS
Variable HR 95% CI P Value
PFS
Age
<60 yr 1
60 yr 1.1 0.8-1.7 .576
Donor type
MRD 1
MUD 0.9 0.6-1.4 .778
Disease risk index
Low 1
Intermediate 2.3 1.1-5.1 .036
High 3.0 1.3-7.0 .011
Very high 4.0 1.3-13 .019
HCT-CI
0-2 1
3 1.5 1.0-2.2 .066
OS
Age
<60 yr 1
60 yr 1.2 0.8-2.0 .346
Donor type
MRD 1
MUD 1.2 0.7-1.9 .513
Disease risk index
Low 1
Intermediate 2.1 0.8-5.2 .127
High 3.4 1.3-9.1 .013
Very high 4.0 1.1-14 .029
HCT-CI
0-2 1
3 1.7 1.1-2.8 .018
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This large single-center cohort analysis suggests that our
FBx-ATG RIC regimen results in low NRM. We estimated an
early NRM at day þ100 of only 5%, even though our patient
population had a high median age (59 years), a high rate of
comorbidities (46%with HCT-CI3), and a high prevalence of
measurable disease (37%), supporting the low early toxicityTable 3
Causes of Death (n ¼ 80)
Cause n
Nonrelapse death 43
Infection and acute GVHD 16
Infection and chronic GVHD 12
Infection without GVHD 6
Cardiac dysfunction 3
Sinusoidal obstruction syndrome 2
Secondary cancer 2
Graft failure 1
Cerebral hemorrhage 1
Relapse-related death 37of this conditioning platform. The low incidence of grade
III-IV acute GVHD (9%), likely related to the use of r-ATG,
contributed to this result. Overall, the NRM in our study
cohort compares satisfactorily with that reported by Storb
et al. [18] after an NMA regimen (day þ100 and 1-year NRM
of 4% and 15%, respectively) in patients with a median age of
56 years (range, 17 to 74 years). It is important to observe
that HCT-CI, but not age, was the determinant of OS, sug-
gesting that age alone is not a sufﬁcient parameter for allo-
cating patients to less-intensive approaches, as reported
previously [19].
The incidence of extensive chronic GVHD in our cohort
was low at 22%, and 79% of patients free of disease at 1 year
after allo-HSCT were also living without GVHD. This could be
considered a surrogate marker for preserved quality of life in
the absence of a prospective assessment. We found that this
conditioning platform allows a low prevalence of persistent
extensive chronic GVHD, contributing to the overall safety
proﬁle. This ﬁnding supports the important contribution of
r-ATG in this setting.
The use of r-ATG remains controversial, especially in the
setting of MRD allo-HSCT. Soiffer et al. [20] reported that
in vivo T cell depletion with r-ATG at a median dose of 7 mg/
kg resulted in a higher incidence of relapse compared with T
cellereplete allo-HSCT. Conversely, we and other groups
have demonstrated that an r-ATG dose of approximately
5 mg/kg produces effective GVHD prophylaxis without
increasing the incidence of relapse [7,8,21,22]. These discor-
dant results underscore the impact of r-ATG dose modula-
tion. Although the optimal dose has not been established, we
propose the hypothesis that 5 mg/kg could approach an
acceptable compromise, with lower doses associated with
insufﬁcient GVHD prophylaxis [5,6] and higher doses asso-
ciated with increased risk of relapse [20].
Figure 2. Impacts of HCT-CI (A) and DRI (B) on OS.
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tious complications. Although we did not evaluate such
complications in the present study, we recently reported a
large cohort of patients who presentedwith cytomegalovirus
(CMV) reactivation after allo-HSCT and showed that in vivo
T cell depletion was not associated with an increased CMV
reactivation or CMV-related disease [23].
Regarding the efﬁcacy of our proposed approach, the
incidence of relapse was 36% at 4 years, conﬁrming that the
antitumor effect of the FBx-ATG regimen compares favorably
with that of true NMA regimens. Several previous studies
reported a cumulative incidence of relapse approaching 50%
after allo-HSCT with a Flu plus 2-Gy TBI conditioning
regimen [6,18,24]. In our series of patients undergoing allo-
HSCT from an MRD or a 10/10-matched MUD, this anti-
tumor effect, in combination with a low NRM, resulted in
promising OS (73% at 1 year and 54% at 4 years), particularly
when considering the poor prognostic features of the cohort
(ie, few patients with a lowDRI, amedian age of 59 years, and
signiﬁcant comorbidities in approximately 50%). The prom-
ising low-toxicity proﬁle found in the present study was alsorecently reported by our group in the setting of trans-
plantation from HLA-mismatched unrelated donors [9].
In summary, all of the changes that have occurred over
the years, including r-ATG dose modulation and Bu admin-
istration [25-27], have led to the development of our FBx-
ATG platform with low toxicity but an active antitumor
effect. These results were achieved and maintained with a
minimum follow-up of 7 months and a median follow-up of
28 months, with some patients undergoing allo-HSCT more
than 6 years earlier. This ﬁnding supports the evidence of a
persistent antitumor effect long after allo-HSCT. Multivariate
analysis identiﬁed the DRI as the strongest marker for poor
survival, demonstrating that post-transplantation relapse in
patients with high-risk features after RIC allo-HSCT remains
a major concern. With its high predictive value in our series,
the DRI is an interesting tool for stratifying patients based on
the risk of relapse rather than on disease type, helping
address the issue of series with various diagnoses. Thus, we
suppose that the DRI could be useful for personalizing the
choice of either conditioning regimen or posteallo-HSCT
treatments in a risk-adapted strategy. Indeed, our FBx-ATG
regimen could be reserved for patients at low and interme-
diate risk, with more-intensive approaches provided for
high-risk and very-high-risk patients, who achieved a 2-year
OS of <50% with the FBx-ATG regimen. From this perspec-
tive, the increased intensity afforded by higher Bu doses
could represent an interesting improvement in the FBx-ATG
platform to address the issue of high-risk diseases. Some
groups have previously showed that myeloablative doses of
i.v. Bu in the FBx-ATG regimen provide both the low NRM
observed with RIC regimens and the high disease control
observed with standard MAC regimens, even in patients of
advanced age and/or with comorbidities [28-30]. This evo-
lution, from the RIC versus MAC paradigm to a myeloablative
regimen with reduced toxicity (MA/RTC), highlights the
critical role of conditioning intensity and opens up the pos-
sibility of myeloablative approaches in a population histori-
cally excluded from standard MAC regimens [31].
We conclude that the FBx-ATG RIC platform reported here
approaches an acceptable balance between toxicity and efﬁ-
cacy, resulting in low mortality and long-term disease-free
survival with preserved quality of life. However, high-risk dis-
ease remains a concern, dictating the need for disease con-
trol strategies through MA/RTC and/or post-transplantation
treatments.ACKNOWLEDGMENTS
The authors thank Professor Borje S. Andersson (M.D.
Anderson Cancer Center, Houston, TX) for his advice and
critical review of themanuscript. They also thank the nursing
staff for the excellent patient care.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Financial disclosure: The authors have nothing to disclose.REFERENCES
1. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute
graft-versus-host disease. N Engl J Med. 2005;353:1321-1331.
2. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell
transplantation in older patients with hematologic malignancies:
replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
Blood. 2001;97:3390-3400.
3. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-
related mortality following unrelated donor stem cell transplantation
by using a nonmyeloablative conditioning regimen. Blood. 2002;99:
1071-1078.
R. Devillier et al. / Biol Blood Marrow Transplant 20 (2014) 370e3743744. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell
transplantation and cell therapy as an alternative to conventional bone
marrow transplantation with lethal cytoreduction for the treatment of
malignant and nonmalignant hematologic diseases. Blood. 1998;91:
756-763.
5. Blaise D, Farnault L, Faucher C, et al. Reduced-intensity conditioning
with Fludarabin, oral busulfan, and thymoglobulin allows long-term
disease control and low transplant-related mortality in patients with
hematological malignancies. Exp Hematol. 2010;38:1241-1250.
6. Blaise D, Tabrizi R, Boher JM, et al. Randomized study of 2 reduced-
intensity conditioning strategies for human leukocyte antigen-matched,
related allogeneic peripheral blood stem cell transplantation: prospec-
tive clinical and socioeconomic evaluation. Cancer. 2013;119:602-611.
7. Crocchiolo R, Esterni B, Castagna L, et al. Two days of antithymocyte
globulin are associated with a reduced incidence of acute and chronic
graft-versus-host disease in reduced-intensity conditioning trans-
plantation for hematologic diseases. Cancer. 2013;119:986-992.
8. Devillier R, Crocchiolo R, Castagna L, et al. The increase from 2.5 to 5
mg/kg of rabbit anti-thymocyte globulin dose in reduced intensity
conditioning reduces acute and chronic GVHD for patients with
myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant.
2012;47:639-645.
9. Devillier R, Furst S, Crocchiolo R, et al. A conditioning platform based on
ﬂudarabine, busulfan and two days of rabbit antithymocyte globulin
results in promising results in patients undergoing allogeneic trans-
plantation from both matched and mismatched unrelated donor. Am J
Hematol. 2013. http://dx.doi.org/10.1002/ajh.23592.
10. Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients
undergoing allogeneic stem cell transplantation. Blood. 2012;120:
905-913.
11. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation
(HCT)-speciﬁc comorbidity index: a new tool for risk assessment
before allogeneic HCT. Blood. 2005;106:2912-2919.
12. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-
versus-host disease in human recipients of marrow from HLA-
matched sibling donors. Transplantation. 1974;18:295-304.
13. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host
syndrome in man: a long-term clinicopathologic study of 20 Seattle
patients. Am J Med. 1980;69:204-217.
14. Fine J. A proportional hazards model for the subdistribution of a
competing risk. J Am Stat Assoc. 1999;94:496-509.
15. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure proba-
bilities in the presence of competing risks: new representations of old
estimators. Stat Med. 1999;18:695-706.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457-481.
17. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:
187-220.
18. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and
graft-versus-tumor effects after allogeneic hematopoietic cell trans-
plantation. J Clin Oncol. 2013;31:1530-1538.
19. El Kourashy S, Williamson T, Chaudhry MA, et al. Inﬂuence of comor-
bidities on transplant outcomes in patients aged 50 years or more aftermyeloablative conditioning incorporating ﬂudarabine, BU and ATG.
Bone Marrow Transplant. 2011;46:1077-1083.
20. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation
with antieT-cell antibodies on the outcome of reduced-intensity
allogeneic hematopoietic stem cell transplantation for hematologic
malignancies. Blood. 2011;117:6963-6970.
21. Russell JA, Turner AR, Larratt L, et al. Adult recipients of matched
related donor blood cell transplants given myeloablative regimens
including pretransplant antithymocyte globulin have lower mortality
related to graft-versus-host disease: a matched pair analysis. Biol Blood
Marrow Transplant. 2007;13:299-306.
22. Duggan P, Booth K, Chaudhry A, et al. Unrelated donor BMT recipients
given pretransplant low-dose antithymocyte globulin have outcomes
equivalent to matched sibling BMT: a matched pair analysis. Bone
Marrow Transplant. 2002;30:681-686.
23. Venton G, Crocchiolo R, Furst S, et al. Risk factors of ganciclovir-related
neutropenia after allogeneic stem cell transplantation: a retrospective
monocentre study on 547 patients. Clin Microbiol Infect. 2013. http://
dx.doi.org/10.1111/1469-0691.12222.
24. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic
hematopoietic cell transplantation in patients with acute myeloid
leukemia. J Clin Oncol. 2010;28:2859-2867.
25. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmaco-
kinetics of intravenous busulfan when used with oral busulfan and
cyclophosphamide as pretransplantation conditioning therapy: a phase
I study. Biol Blood Marrow Transplant. 2000;6:548-554.
26. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with
intravenous busulfan and cyclophosphamide (IV BuCy2) for hemato-
logic malignancies prior to allogeneic stem cell transplantation: a
phase II study. Biol Blood Marrow Transplant. 2002;8:145-154.
27. Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality
rates associated with i.v. busulfan and cyclophosphamide vs other
preparative regimens in allogeneic bone marrow transplantation for
chronic myelogenous leukemia: Bayesian sensitivity analyses of
confounded treatment and center effects. Bone Marrow Transplant.
2004;33:1191-1199.
28. Alatrash G, de Lima M, Hamerschlak N, et al. Myeloablative reduced-
toxicity i.v. busulfan-ﬂudarabine and allogeneic hematopoietic stem
cell transplant for patients with acute myeloid leukemia or myelo-
dysplastic syndrome in the sixth through eighth decades of life. Biol
Blood Marrow Transplant. 2011;17:1490-1496.
29. Andersson BS, de Lima M, Thall PF, et al. Once-daily i.v. busulfan and
ﬂudarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and
cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy
in AML/MDS. Biol Blood Marrow Transplant. 2008;14:672-684.
30. Liu H, Zhai X, Song Z, et al. Busulfan plus ﬂudarabine as a myeloablative
conditioning regimen compared with busulfan plus cyclophosphamide
for acute myeloid leukemia in ﬁrst complete remission undergoing
allogeneic hematopoietic stem cell transplantation: a prospective and
multicenter study. J Hematol Oncol. 2013;6:15.
31. Blaise D, Castagna L. Do different conditioning regimens really make a
difference? Hematology Am Soc Hematol Educ Program. 2012;2012:
237-245.
